These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
245 related articles for article (PubMed ID: 30844389)
1. High density is a property of slow-cycling and treatment-resistant human glioblastoma cells. Sabelström H; Quigley DA; Fenster T; Foster DJ; Fuchshuber CAM; Saxena S; Yuan E; Li N; Paterno F; Phillips JJ; James CD; Norling B; Berger MS; Persson AI Exp Cell Res; 2019 May; 378(1):76-86. PubMed ID: 30844389 [TBL] [Abstract][Full Text] [Related]
3. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells. Vengoji R; Macha MA; Nimmakayala RK; Rachagani S; Siddiqui JA; Mallya K; Gorantla S; Jain M; Ponnusamy MP; Batra SK; Shonka N J Exp Clin Cancer Res; 2019 Jun; 38(1):266. PubMed ID: 31215502 [TBL] [Abstract][Full Text] [Related]
4. Nuclear factor I A promotes temozolomide resistance in glioblastoma via activation of nuclear factor κB pathway. Yu X; Wang M; Zuo J; Wahafu A; Mao P; Li R; Wu W; Xie W; Wang J Life Sci; 2019 Nov; 236():116917. PubMed ID: 31614149 [TBL] [Abstract][Full Text] [Related]
5. Divergent evolution of temozolomide resistance in glioblastoma stem cells is reflected in extracellular vesicles and coupled with radiosensitization. Garnier D; Meehan B; Kislinger T; Daniel P; Sinha A; Abdulkarim B; Nakano I; Rak J Neuro Oncol; 2018 Jan; 20(2):236-248. PubMed ID: 29016925 [TBL] [Abstract][Full Text] [Related]
6. Targeted nanocomplex carrying siRNA against MALAT1 sensitizes glioblastoma to temozolomide. Kim SS; Harford JB; Moghe M; Rait A; Pirollo KF; Chang EH Nucleic Acids Res; 2018 Feb; 46(3):1424-1440. PubMed ID: 29202181 [TBL] [Abstract][Full Text] [Related]
7. The TNF receptor family member Fn14 is highly expressed in recurrent glioblastoma and in GBM patient-derived xenografts with acquired temozolomide resistance. Hersh DS; Harder BG; Roos A; Peng S; Heath JE; Legesse T; Kim AJ; Woodworth GF; Tran NL; Winkles JA Neuro Oncol; 2018 Sep; 20(10):1321-1330. PubMed ID: 29897522 [TBL] [Abstract][Full Text] [Related]
8. Temozolomide-induced increase of tumorigenicity can be diminished by targeting of mitochondria in in vitro models of patient individual glioblastoma. William D; Walther M; Schneider B; Linnebacher M; Classen CF PLoS One; 2018; 13(1):e0191511. PubMed ID: 29352318 [TBL] [Abstract][Full Text] [Related]
9. Cordycepin Augments the Chemosensitivity of Human Glioma Cells to Temozolomide by Activating AMPK and Inhibiting the AKT Signaling Pathway. Bi Y; Li H; Yi D; Sun Y; Bai Y; Zhong S; Song Y; Zhao G; Chen Y Mol Pharm; 2018 Nov; 15(11):4912-4925. PubMed ID: 30336060 [TBL] [Abstract][Full Text] [Related]
10. BMP4 and Temozolomide Synergize in the Majority of Patient-Derived Glioblastoma Cultures. Verploegh ISC; Conidi A; El Hassnaoui H; Verhoeven FAM; Korporaal AL; Ntafoulis I; van den Hout MCGN; Brouwer RWW; Lamfers MLM; van IJcken WFJ; Huylebroeck D; Leenstra S Int J Mol Sci; 2024 Sep; 25(18):. PubMed ID: 39337661 [TBL] [Abstract][Full Text] [Related]
11. Anticancer drug candidate CBL0137, which inhibits histone chaperone FACT, is efficacious in preclinical orthotopic models of temozolomide-responsive and -resistant glioblastoma. Barone TA; Burkhart CA; Safina A; Haderski G; Gurova KV; Purmal AA; Gudkov AV; Plunkett RJ Neuro Oncol; 2017 Feb; 19(2):186-196. PubMed ID: 27370399 [TBL] [Abstract][Full Text] [Related]
12. Sox2, a stemness gene, regulates tumor-initiating and drug-resistant properties in CD133-positive glioblastoma stem cells. Song WS; Yang YP; Huang CS; Lu KH; Liu WH; Wu WW; Lee YY; Lo WL; Lee SD; Chen YW; Huang PI; Chen MT J Chin Med Assoc; 2016 Oct; 79(10):538-45. PubMed ID: 27530866 [TBL] [Abstract][Full Text] [Related]
14. LGR5 promotes tumorigenicity and invasion of glioblastoma stem-like cells and is a potential therapeutic target for a subset of glioblastoma patients. Xie Y; Sundström A; Maturi NP; Tan EJ; Marinescu VD; Jarvius M; Tirfing M; Jin C; Chen L; Essand M; Swartling FJ; Nelander S; Jiang Y; Uhrbom L J Pathol; 2019 Feb; 247(2):228-240. PubMed ID: 30357839 [TBL] [Abstract][Full Text] [Related]
15. Combined treatment with 2'-hydroxycinnamaldehyde and temozolomide suppresses glioblastoma tumorspheres by decreasing stemness and invasiveness. Jeong H; Park J; Shim JK; Lee JE; Kim NH; Kim HS; Chang JH; Yook JI; Kang SG J Neurooncol; 2019 May; 143(1):69-77. PubMed ID: 30887242 [TBL] [Abstract][Full Text] [Related]
16. Polyethylenimine-Spherical Nucleic Acid Nanoparticles against Gli1 Reduce the Chemoresistance and Stemness of Glioblastoma Cells. Melamed JR; Ioele SA; Hannum AJ; Ullman VM; Day ES Mol Pharm; 2018 Nov; 15(11):5135-5145. PubMed ID: 30260647 [TBL] [Abstract][Full Text] [Related]
17. miR128-1 inhibits the growth of glioblastoma multiforme and glioma stem-like cells via targeting BMI1 and E2F3. Shan ZN; Tian R; Zhang M; Gui ZH; Wu J; Ding M; Zhou XF; He J Oncotarget; 2016 Nov; 7(48):78813-78826. PubMed ID: 27705931 [TBL] [Abstract][Full Text] [Related]
18. Momelotinib sensitizes glioblastoma cells to temozolomide by enhancement of autophagy via JAK2/STAT3 inhibition. Liu T; Li A; Xu Y; Xin Y Oncol Rep; 2019 Mar; 41(3):1883-1892. PubMed ID: 30664175 [TBL] [Abstract][Full Text] [Related]
19. Inhibition of cyclin E1 overcomes temozolomide resistance in glioblastoma by Mcl-1 degradation. Liang H; Chen Z; Sun L Mol Carcinog; 2019 Aug; 58(8):1502-1511. PubMed ID: 31045274 [TBL] [Abstract][Full Text] [Related]
20. Targeting Glioma Initiating Cells with A combined therapy of cannabinoids and temozolomide. López-Valero I; Saiz-Ladera C; Torres S; Hernández-Tiedra S; García-Taboada E; Rodríguez-Fornés F; Barba M; Dávila D; Salvador-Tormo N; Guzmán M; Sepúlveda JM; Sánchez-Gómez P; Lorente M; Velasco G Biochem Pharmacol; 2018 Nov; 157():266-274. PubMed ID: 30195736 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]